Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B London

Showing results (231-240 of 310) with videos related to

Pageof 31
Sort By:
Pediatric Blood & Cancer|August 12, 2021
Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumorsHolly J Meany, Brigitte C Widemann, Pamela S Hinds, et al.
Journal of Neuro-Oncology|July 23, 2017
Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survivalAmanda E Marinoff, Clement Ma, Dongjing Guo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2020
Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 StudyKevin X Liu, Arlene Naranjo, Fan F Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2004
Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882Barbara Cushing, Roger Giller, John W Cullen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2021
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology GroupMeredith S Irwin, Arlene Naranjo, Fan F Zhang, et al.
Blood|February 29, 2012
Overcoming reprogramming resistance of Fanconi anemia cellsLars U W Müller, Michael D Milsom, Chad E Harris, et al.
Pediatric Blood & Cancer|June 14, 2021
Pyruvate kinase deficiency in childrenSatheesh Chonat, Stefan W Eber, Susanne Holzhauer, et al.
Frontiers in Immunology|July 4, 2018
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2011
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology GroupJudith G Villablanca, Wendy B London, Arlene Naranjo, et al.
Frontiers in Immunology|July 27, 2018
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
Pageof 31

Showing results (231-240 of 310) with videos related to

Sort By:
Pageof 31
Pediatric Blood & Cancer|August 12, 2021
Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumorsHolly J Meany, Brigitte C Widemann, Pamela S Hinds, et al.
Journal of Neuro-Oncology|July 23, 2017
Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survivalAmanda E Marinoff, Clement Ma, Dongjing Guo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2020
Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 StudyKevin X Liu, Arlene Naranjo, Fan F Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2004
Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882Barbara Cushing, Roger Giller, John W Cullen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2021
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology GroupMeredith S Irwin, Arlene Naranjo, Fan F Zhang, et al.
Blood|February 29, 2012
Overcoming reprogramming resistance of Fanconi anemia cellsLars U W Müller, Michael D Milsom, Chad E Harris, et al.
Pediatric Blood & Cancer|June 14, 2021
Pyruvate kinase deficiency in childrenSatheesh Chonat, Stefan W Eber, Susanne Holzhauer, et al.
Frontiers in Immunology|July 4, 2018
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2011
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology GroupJudith G Villablanca, Wendy B London, Arlene Naranjo, et al.
Frontiers in Immunology|July 27, 2018
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
Pageof 31